Physician
Central Arkansas Radiation Therapy Institute INC
Central Arkansas Radiation Therapy Institute INC was paid $11.09M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 96413, Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance — 34% of everything it billed.
33Billing provider infoCENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC
LITTLE ROCK, AR 72205
LITTLE ROCK, AR 72205
33aNPI1508147810assigned 08/31/2011
33bProvider typeDiagnostic Radiology Physician
28Total paid$11.09M
24GClaims321,535
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Diagnostic Radiology Physician providers in Arkansas
Rank by total paid#1 of 121
Median peer was paid$28K
This provider vs. median392×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,466 | $1.50M | |
| 2019 | 48,201 | $1.96M | |
| 2020 | 40,072 | $1.44M | |
| 2021 | 49,884 | $1.64M | |
| 2022 | 54,191 | $2.06M | |
| 2023 | 51,847 | $1.83M | |
| 2024incomplete | 30,874 | $652K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 34% | 18,108 | 11,896 | $3.75M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 28,905 | 23,839 | $1.42M |
| 96375 | Therapeutic injection; each additional sequential IV push | 7.1% | 23,034 | 14,772 | $793K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 7.1% | 5,578 | 4,904 | $792K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 5.0% | 945 | 765 | $553K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 4.7% | 10,933 | 7,094 | $519K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 3,541 | 3,124 | $430K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.0% | 14,443 | 12,874 | $332K |
| 96367 | 2.9% | 7,645 | 5,173 | $320K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 65,684 | 45,069 | $284K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 2.5% | 2,852 | 1,779 | $274K |
| 80053 | Comprehensive metabolic panel | 2.5% | 44,849 | 34,116 | $274K |
66 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 2.2% | 3,080 | $247K |
| 96417 | 1.6% | 1,802 | $178K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 1.3% | 1,692 | $139K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,546 | $95K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,809 | $86K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 488 | $64K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 17 | $61K |
| 82728 | <1% | 9,400 | $61K | |
| 82378 | <1% | 4,630 | $52K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 151 | $46K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 666 | $39K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 24 | $30K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 775 | $26K |
| 96415 | <1% | 580 | $25K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 740 | $22K |
| 83615 | <1% | 5,166 | $19K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,897 | $13K |
| 82607 | <1% | 1,835 | $13K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 46 | $13K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 179 | $11K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,567 | $11K |
| 82746 | <1% | 1,557 | $11K | |
| 51798 | <1% | 1,789 | $9K | |
| 83550 | <1% | 1,745 | $8K | |
| 84550 | <1% | 2,477 | $7K | |
| 83540 | <1% | 1,757 | $6K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 354 | $6K |
| 86300 | <1% | 399 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 81 | $5K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 115 | $4K |
| 78306 | <1% | 67 | $4K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 143 | $3K |
| 82565 | <1% | 1,019 | $3K | |
| 76642 | <1% | 63 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 44 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 304 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 27 | $2K |
| 96411 | <1% | 22 | $1K | |
| J3490 | Unclassified drugs | <1% | 1,585 | $1K |
| 84165 | <1% | 233 | $1K | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 80 | $1K |
| 86334 | <1% | 113 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 181 | $1K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 15 | $857.50 |
| 82784 | <1% | 128 | $774.17 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 27 | $731.40 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,598 | $727.77 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $430.99 |
| 83735 | <1% | 93 | $411.05 | |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | <1% | 33 | $373.76 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 49 | $359.86 |
| 90674 | <1% | 28 | $353.64 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 62 | $337.50 |
| S0028 | Injection, famotidine, 20 mg | <1% | 430 | $296.99 |
| 81000 | <1% | 344 | $292.62 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 16 | $282.51 |
| 81003 | <1% | 1,727 | $240.04 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 22 | $201.60 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 38 | $121.50 |
| 76937 | <1% | 13 | $113.88 | |
| 85045 | <1% | 21 | $93.36 | |
| 82668 | <1% | 14 | $80.52 | |
| 84436 | <1% | 21 | $44.50 | |
| 85652 | <1% | 15 | $31.40 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 46 | $7.74 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHEAD, ADAM (CEO)
Parent organizationCENTRAL ARKANSAS RADIATION THERAPY INST INC
| Provider | Location | Paid |
|---|---|---|
| Central Arkansas Radiation Therapy Institute INC | Little Rock, AR | $3.55M |
| Carti Oncology Solutions LLC | Little Rock, AR | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.